à 
Amphithéâtre Justine-Lacoste-Beaubien
3175, Chemin de la Côte-Sainte-Catherine
Montréal (QC) Canada  H3T 1C5

Conférence scientifique | Centre de recherche du CHU Sainte-Justine

Conférencier :
Robert P. Jankov, MB,BS PhD FRACP

  • Néonatologiste, Centre hospitalier pour enfants de l'est de l'Ontario (CHEO) et Hôpital d'Ottawa
  • Professeur agrégé, Département de pédiatrie, Université d'Ottawa
  • Chercheur principal, Institut de recherche du CHEO

Résumé :
Dr. Jankov’s research has continuously focused upon an improved understanding of chronic pulmonary vascular disease, which in the neonate predominantly occurs in the context of bronchopulmonary dysplasia (BPD) and other developmental lung disorders. His research interests include the cellular and molecular mechanisms of vascular remodelling, right-ventricular dysfunction and nitric oxide unresponsiveness in pulmonary hypertension during early life. The overall objective of his research program is to delineate critical factors underlying pathogenesis that will inform new therapies. Current areas of focus using novel animal models developed in his laboratory include therapies targeting Rho-kinase activity, thrombospondin signaling and arginine-nitric oxide dysfunction. The CIHR, Heart and Stroke Foundation and the Physicians’ Services Incorporated Foundation currently fund his work.

Biographie :
Robert Jankov
obtained his MB, BS at the University of Melbourne, Australia and completed his residency training in paediatrics at the Royal Children’s Hospital, also in Melbourne. He subsequently completed a Clinical Fellowship in Neonatal-Perinatal Medicine at the University of Toronto from1996 to 1999, which was followed by a PhD from 2001 to 2004 in the Department of Physiology, University of Toronto. He was previously a Staff Neonatologist and Senior Scientist at Sunnybrook Health Sciences Centre and the Hospital for Sick Children, Toronto.

Conférence prononcée en anglais.

Chronic pulmonary hypertension in neonates: New insights, new targets